Seroatlas · Human Serome Atlas

RFLNA

Refilin-A

Also known as: Cfm2, FAM101A, FLJ44614, RefilinA, RFLA_HUMAN

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession: Q6ZTI6
Gene: RFLNA
Ensembl: ENSG00000178882
Chromosome: 12
Canonical length: 216 aa
Protein class: Predicted intracellular proteins
Subcellular location: Focal adhesion sites

OverviewNCBI Gene

Predicted to enable filamin binding activity. Predicted to be involved in several processes, including actin filament bundle organization; negative regulation of bone mineralization involved in bone maturation; and negative regulation of chondrocyte development. Predicted to be located in cytoplasm and cytoskeleton. Predicted to be active in actin filament bundle. [provided by Alliance of Genome Resources, Jul 2025]

Canonical amino-acid sequenceUniProt

216 residues, UniProt reviewed canonical sequence.

>Q6ZTI6|RFLNA
     1  MVGHLHLQGM EDSLKEQGRE GLLDSPDSGL PPSPSPSPPF YSLAPGILDA RAGGAGASSE
    61  PPGPSEARAP PSQLPNPPAS EMRPRMLPVF FGESIKVNPE PTHEIRCNSE VKYASEKHFQ
   121  DKVFYAPVPT VTAYSETIVA APNCTWRNYR SQLTLEPRPR ALRFRSTTII FPKHARSTFR
   181  TTLHCSLGRP SRWFTASVQL QLCQDPAPSL LGPATL

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against RFLNA can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability: Intracellular
Secreted: No
Transmembrane segments: 0
Mean surface accessibility (rSASA): 0.6
Highest tissue expression: 89 nTPM

Expression across tissuesHPA

Tissue

stomach: 89 nTPM
colon: 14 nTPM
small intestine: 14 nTPM
duodenum: 13 nTPM
cervix: 13 nTPM
rectum: 9.8 nTPM

Single-cell type

bergmann glia: 192 nCPM
foveolar cells: 165 nCPM
early spermatids: 90 nCPM
epicardial cells: 84 nCPM
late spermatids: 83 nCPM
brain inhibitory neurons: 74 nCPM

Immune cell

basophil: 0 nTPM
classical monocyte: 0 nTPM
eosinophil: 0 nTPM
gdT-cell: 0 nTPM
intermediate monocyte: 0 nTPM
MAIT T-cell: 0 nTPM

Brain region

pons: 42 nTPM
medulla oblongata: 23 nTPM
cerebellum: 12 nTPM
choroid plexus: 12 nTPM
midbrain: 9.1 nTPM
spinal cord: 8.8 nTPM

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance): 1.4
gnomAD pLI: 0.23
DepMap mean gene effect: -0.05
DepMap dependency class: selective

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 4% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

filamin binding

Cellular components

actin filament bundle

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

InteractionsUniProt · HPA

Protein binding partners of RFLNA in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads RFLNA as an antibody target. Whether an autoantibody or antibody against RFLNA could matter depends on whether native RFLNA is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

RFLNA is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.

Annotation status

The present source text does not explicitly label RFLNA as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Loading the interactive Seroatlas protein explorer...